Aristo Bio-Tech and Lifescience Balance Sheet Health
Financial Health criteria checks 5/6
Aristo Bio-Tech and Lifescience has a total shareholder equity of ₹336.1M and total debt of ₹208.8M, which brings its debt-to-equity ratio to 62.1%. Its total assets and total liabilities are ₹1.3B and ₹936.8M respectively. Aristo Bio-Tech and Lifescience's EBIT is ₹69.2M making its interest coverage ratio 4.1. It has cash and short-term investments of ₹6.4M.
Key information
62.1%
Debt to equity ratio
₹208.76m
Debt
| Interest coverage ratio | 4.1x |
| Cash | ₹6.37m |
| Equity | ₹336.09m |
| Total liabilities | ₹936.78m |
| Total assets | ₹1.27b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: ARISTO's short term assets (₹1.1B) exceed its short term liabilities (₹835.7M).
Long Term Liabilities: ARISTO's short term assets (₹1.1B) exceed its long term liabilities (₹101.1M).
Debt to Equity History and Analysis
Debt Level: ARISTO's net debt to equity ratio (60.2%) is considered high.
Reducing Debt: ARISTO's debt to equity ratio has reduced from 127.9% to 62.1% over the past 5 years.
Debt Coverage: ARISTO's debt is well covered by operating cash flow (36.4%).
Interest Coverage: ARISTO's interest payments on its debt are well covered by EBIT (4.1x coverage).